This provides you unprecedented ease, efficiency and economics of determining how well any needed therapies, or changes in health or lifestyle may affect your patient's Sleep Apnea. This can be done at any point over the 3-5 year battery life. Powered by a lithium battery, the NightOwl isREUSABLE with the ability to monitor up to 100 hours of data, enabling you to obtain an assessment of your sleep over multiple nights for the most realistic depiction of your sleep patterns. This makes self-administering the study about as easy as putting on a band-aid. Held in place with a simple adhesive strip, the device transmits its findings wirelessly to the nearby cell phone, which then transmits the recorded data directly to your physician the next morning. Across the continuum of care, buyers and investors are looking for well established, profitable businesses and offering strong valuations and options for management.ĭo you know the current market value of your business? We do! We are here to help you plan, prepare, explore and succeed in executing your strategic options.Ĭontact Paragon Ventures for more information.Harnessing the connectivity of bluetooth, the internet and smartphones, the tiny NightOwl sensor is activated and placed on the fingertip, using light transmission to monitor tiny yet identifiable changes in the vessels in the distal tip of the finger. There is unprecedented capital in market, the lowest interest rates in US history and strong acquirer motivations for high quality healthcare companies. The M&A market for healthcare companies continues to strengthen in 2021 and ahead of the projected increases in US capital gains taxes. The transaction is not material to ResMed’s consolidated financial results its financial terms were not disclosed. “It will take the combined efforts of sleep labs and connected home solutions like NightOwl to identify a significant portion of the hundreds of millions of people suffering from this disease that don’t even know it.”Įctosense will operate within ResMed’s Sleep and Respiratory Care business. “ResMed has the global reach and passionate ambition to help increase patient access to Ectosense’s proven diagnostic solution and a path to better sleep and overall health,” added Frederik Massie, chief technology officer and cofounder of Ectosense. We’re excited to welcome Ectosense’s life-changing team to the ResMed family.” “Ectosense’s clinically validated, consumer-friendly devices will enable us to help millions of people in many markets improve their sleep and overall health.
“In developing markets, we need to make sleep tests affordable, accessible and easy to use,” said Justin Leong, ResMed president of Asia and Latin America. For millions of people, their best night’s sleep must start with a diagnosis.” “We believe Ectosense’s digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. “Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea,” said Jim Hollingshead, ResMed president of Sleep and Respiratory Care. ResMed has distributed NightOwl in Australia, New Zealand, and India since 2020 under the brand “ResMed onesleeptest™” and has been a minority investor in Ectosense since July 2020. Ectosense’s FDA-approved NightOwl™ is sold in the United States, Australia, New Zealand, India, and parts of Europe. SAN DIEGO – ResMed has completed the acquisition of Ectosense, a cloud-connected home sleep test device.
0 kommentar(er)
